Promotie onderzoek

The landscape of drug development as well as clinical practice has been changing  over the last decennium, with the increasing availability and use of biobased therapies. This research is now focusing on the use and therapeutic drug monitoring of biobased factor VIII therapies in hemophilia A patients.

The aim of this project is to provide insight in the use of biologicals, including biosimilars, in clinical practice and add to the safe and effective use of these agents. We also provide guidance on the implementation of biosimilars in clinical practice from the perspective of different stakeholders including prescribers, pharmacists and patients.

Assessment of saliva/plasma ratio for drugs administered to (premature) neonates.

Therapeutic drug monitoring of clotting factor concentrates in patients Willebrand disease undergoing surgery.

Development of a webportal for TDM requests. Aplication of neural networks (deep learning) for population analysis. 

• A prospective observational PK/PD to study the target attainment for β-lactam antibiotics in critical ill patients and its associated risk factors.
• A multi-centre, randomised controlled trial to assess the efficacy and cost-effectiveness of model-based TDM of beta-lactam and fluoroquinolone antibiotics.